LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib

This study is testing whether adding targeted local treatment (such as radiation or surgery) to specific sites of cancer progression can extend the benefit of osimertinib (a targeted oral therapy) in patients with advanced lung cancer whose disease has started progressing in only a few areas. **You may be eligible if...** - You are 18 or older - You have advanced non-small cell lung cancer with an EGFR mutation being treated with osimertinib - Your cancer initially responded to osimertinib (at least stable disease for 3 months) - Your cancer is now progressing in 3 or fewer sites (called oligoprogression) - All progressive sites can be safely treated with local therapy **You may NOT be eligible if...** - Your cancer has progressed in more than 3 sites - You do not have an EGFR mutation - You have not had a prior response to osimertinib Talk to your doctor to see if this trial is right for you.